DK0904060T3 - Antifungale præparater med forbedret biotilgængelighed - Google Patents

Antifungale præparater med forbedret biotilgængelighed

Info

Publication number
DK0904060T3
DK0904060T3 DK97923915T DK97923915T DK0904060T3 DK 0904060 T3 DK0904060 T3 DK 0904060T3 DK 97923915 T DK97923915 T DK 97923915T DK 97923915 T DK97923915 T DK 97923915T DK 0904060 T3 DK0904060 T3 DK 0904060T3
Authority
DK
Denmark
Prior art keywords
improved bioavailability
antifungal preparations
antifungal
preparations
bioavailability
Prior art date
Application number
DK97923915T
Other languages
English (en)
Inventor
Lieven Elvire Colette Baert
Geert Verreck
Dany Thone
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26142825&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0904060(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0904060T3 publication Critical patent/DK0904060T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97923915T 1996-05-20 1997-05-12 Antifungale præparater med forbedret biotilgængelighed DK0904060T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96201430 1996-05-20
EP97200698 1997-03-07
PCT/EP1997/002507 WO1997044014A1 (en) 1996-05-20 1997-05-12 Antifungal compositions with improved bioavailability

Publications (1)

Publication Number Publication Date
DK0904060T3 true DK0904060T3 (da) 2004-04-13

Family

ID=26142825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97923915T DK0904060T3 (da) 1996-05-20 1997-05-12 Antifungale præparater med forbedret biotilgængelighed

Country Status (34)

Country Link
US (4) US6509038B2 (da)
EP (1) EP0904060B1 (da)
JP (1) JP3391801B2 (da)
KR (1) KR19990044257A (da)
CN (1) CN1165291C (da)
AR (1) AR007195A1 (da)
AT (1) ATE255883T1 (da)
AU (1) AU722101B2 (da)
BG (1) BG64368B1 (da)
BR (1) BR9706897B1 (da)
CA (1) CA2240161C (da)
CY (1) CY2434B1 (da)
CZ (1) CZ293841B6 (da)
DE (1) DE69726729T2 (da)
DK (1) DK0904060T3 (da)
EA (1) EA001219B1 (da)
EE (1) EE03902B1 (da)
ES (1) ES2212810T3 (da)
HK (1) HK1018002A1 (da)
HR (1) HRP970270B1 (da)
HU (1) HU227745B1 (da)
ID (1) ID16926A (da)
IL (1) IL124935A (da)
MX (1) MX9805418A (da)
MY (1) MY123827A (da)
NO (1) NO320495B1 (da)
NZ (1) NZ330739A (da)
PL (1) PL188566B1 (da)
PT (1) PT904060E (da)
SI (1) SI0904060T1 (da)
SK (1) SK284145B6 (da)
TR (1) TR199801225T2 (da)
TW (1) TW460282B (da)
WO (1) WO1997044014A1 (da)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
PT1039909E (pt) 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
KR100514330B1 (ko) * 1997-12-31 2006-02-17 주식회사 중외제약 난용성 약물을 함유하는 코팅정
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
ES2251985T3 (es) * 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP2072049A3 (en) * 2000-06-22 2009-12-30 Novartis Ag Solid valsartan pharmaceutical compositions
DE10038571A1 (de) * 2000-08-03 2002-02-14 Knoll Ag Zusammensetzungen und Dosierungsformen zur Anwendung in der Mundhöhle bei der Bhandlung von Mykosen
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
CA2438304C (en) 2001-02-14 2011-04-12 Dominique Louis Nestor Ghislain Surleraux Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
HUP0303744A3 (en) 2001-04-09 2008-03-28 Tibotec Pharm Ltd Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors and pharmaceutical compositions containing them
PL209029B1 (pl) 2001-05-11 2011-07-29 Tibotec Pharm Ltd Pochodne 2-aminobenzoksazolo-sulfonamidów jako inhibitory proteazy HIV, oraz kompozycje zawierające te związki
AU2002317063A (en) * 2001-06-12 2002-12-23 Smartrix Technologies Inc Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
KR100455216B1 (ko) * 2001-06-27 2004-11-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 이의 제조 방법
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
BR0212833A (pt) 2001-09-26 2004-10-13 Baxter Int Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
UA79248C2 (en) 2001-11-09 2007-06-11 Janssen Pharmaceutica Nv Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
US6455557B1 (en) 2001-11-28 2002-09-24 Elan Pharmaceuticals, Inc. Method of reducing somnolence in patients treated with tizanidine
US20040220240A1 (en) * 2001-11-28 2004-11-04 Pellegrini Cara A. Method of increasing the extent of absorption of tizanidine
PL216539B1 (pl) 2001-12-21 2014-04-30 Tibotec Pharm Ltd Związki fenylosulfonylowe i zastosowanie związków fenylosulfonylowych
HRP20020124A2 (en) * 2002-02-11 2003-10-31 Pliva D D Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping
ZA200502496B (en) 2002-02-28 2005-10-12 Japan Tobacco Inc Ester compound and medicinal use thereof.
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
DK1517899T3 (da) 2002-05-17 2007-12-03 Tibotec Pharm Ltd Bredspektret substitueret benzisoxazolsulfonamid HIV-proteaseinhibitor
CA2489071A1 (en) * 2002-07-04 2004-01-15 Janssen Pharmaceutica N.V. Solid dispersions comprising two different polymer matrixes
NZ538714A (en) 2002-08-14 2007-03-30 Tibotec Pharm Ltd Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
CN1703200B (zh) * 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
ES2283725T5 (es) * 2003-01-14 2014-11-28 Acino Pharma Ag Composición bioequivalente de itraconazol dispersada en un polímero hidrófilo
CN101091695B (zh) * 2003-02-03 2011-01-19 诺瓦提斯公司 药物制剂
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
US20060172010A1 (en) * 2003-07-17 2006-08-03 Gael Lamoureux Process for preparing particles containing an antiviral
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP4832897B2 (ja) 2003-08-29 2011-12-07 日本たばこ産業株式会社 エステル誘導体及びその医薬用途
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
TW200518742A (en) 2003-09-11 2005-06-16 Tibotec Pharm Ltd Entry inhibitors
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
AU2005219443A1 (en) * 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
JP5073480B2 (ja) 2004-05-07 2012-11-14 セコイア、ファーマシューティカルズ、インコーポレイテッド 耐性防止レトロウイルスプロテアーゼ阻害薬
TW200607503A (en) 2004-05-17 2006-03-01 Tibotec Pharm Ltd 1-heterocyclyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones
EP1751156B1 (en) 2004-05-17 2010-09-15 Tibotec Pharmaceuticals 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido(3,2-b)indol-2-ones useful as anti-infective pharmaceutical agents
JP4879889B2 (ja) 2004-05-17 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド 4−置換−1,5−ジヒドロ−ピリド[3,2−b]インドール−2−オン
WO2005117834A1 (en) * 2004-05-27 2005-12-15 Janssen Pharmaceutica N.V. Solid dispersions of a basic drug compound and a polymer containing acidic groups
KR20050119397A (ko) * 2004-06-16 2005-12-21 보람제약주식회사 고상용해를 이용한 난용성 약물의 가용화 방법과 이를이용한 가용화 조성물
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR100708974B1 (ko) * 2004-07-19 2007-04-18 주식회사종근당 수용성 수지를 이용한 이트라코나졸 고체분산체
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
US9504658B2 (en) 2004-11-09 2016-11-29 Board Of Regents, The University Of Texas System Stabilized HME composition with small drug particles
EP1848430B1 (en) * 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
PL1912626T3 (pl) * 2005-08-08 2016-10-31 Postaci użytkowe o polepszonej biodostępności
ES2571032T3 (es) * 2005-08-08 2016-05-23 Abbvie Deutschland Composiciones de itraconazol con biodisponibilidad mejorada
ES2403006T3 (es) 2005-08-22 2013-05-13 The Johns Hopkins University Antagonistas de la vía Hedgehog para tratar enfermedades
CA2642761A1 (en) * 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
EP2004647A1 (en) 2006-04-03 2008-12-24 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 3,4-dihydro-imidazoý4,5-b¨pyridin-5-ones
GB0607105D0 (en) * 2006-04-10 2006-05-17 Leuven K U Res & Dev Enhancing solubility and dissolution rate of poorly soluble drugs
DK2034975T3 (da) 2006-06-19 2012-07-23 Alpharma Pharmaceuticals Llc Farmaceutiske sammensætninger
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
JP2010506833A (ja) * 2006-10-11 2010-03-04 アルファーマ,インコーポレイテッド 医薬組成物
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CN101835492B (zh) 2007-08-21 2012-11-21 德克萨斯州立大学董事会 用于制药应用的热动力学混合
EP2471516A3 (en) 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
CA2926610A1 (en) 2007-09-27 2009-04-02 Wockhardt Research Centre Pharmaceutical compositions of rhein or diacerein
US20090130160A1 (en) * 2007-11-21 2009-05-21 Fiber Innovation Technology, Inc. Fiber for wound dressing
CA2707161C (en) 2007-11-28 2016-08-16 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome p450 2d6
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
WO2009087410A2 (en) * 2008-01-11 2009-07-16 Cipla Limited Solid pharmaceutical dosage form
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
MX2010009990A (es) 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
EP2285351A2 (en) * 2008-04-15 2011-02-23 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EA200900145A1 (ru) * 2008-12-31 2010-02-26 Открытое Акционерное Общество "Верофарм" Противогрибковое средство для вагинального применения
CN101780046B (zh) * 2009-01-16 2011-09-21 北京化工大学 一种伊曲康唑复合粉体及其制备方法
WO2011074961A1 (en) 2009-12-18 2011-06-23 Frieslandcampina Nederland Holding B.V. Co-processed tablet excipient composition its preparation and use
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
EP2627195B1 (en) * 2010-10-14 2014-08-20 Abbott GmbH & Co. KG Curcuminoid solid dispersion formulation
CN102068416A (zh) * 2010-12-30 2011-05-25 安徽先求药业有限公司 一种含有伊曲康唑的口服固体制剂及其制备方法
JP2014505714A (ja) 2011-02-17 2014-03-06 エフ.ホフマン−ラ ロシュ アーゲー ホットメルト押出法による過冷却液体状態からの活性医薬成分の制御された結晶化方法
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
EP2744481A4 (en) * 2011-08-16 2015-07-01 Merck Sharp & Dohme USE OF INORGANIC MATRIX AND COMBINATIONS OF ORGANIC POLYMERS FOR THE PREPARATION OF STABLE AMORPHOUS DISPERSIONS
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
WO2013037396A1 (en) * 2011-09-12 2013-03-21 Bioneer A/S Solution of polymer in api for a solid dosage form
EP2760864B1 (en) 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
KR20200065093A (ko) 2012-06-21 2020-06-08 메인 파마 인터내셔널 프로프라이어터리 리미티드 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법
CN104602673B (zh) * 2012-07-17 2017-11-24 陶氏环球技术有限责任公司 包含高度取代的羟基烷基甲基纤维素的固体分散体
KR20150084873A (ko) 2012-11-19 2015-07-22 닥터 레디스 레보러터리즈 리미티드 Cetp 억제제의 약학적 조성물
JP6192244B2 (ja) 2013-01-22 2017-09-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 改良されたバイオアベイラビリティを有する薬学的組成物
CN104721827A (zh) * 2013-12-18 2015-06-24 博瑞生物医药技术(苏州)有限公司 一种难溶性抗真菌药物固体分散体及其制备方法
CN105873954B (zh) 2014-01-16 2019-03-29 陶氏环球技术有限责任公司 用于3d打印的支撑材料
JP6810060B2 (ja) * 2015-06-09 2021-01-06 ダウ グローバル テクノロジーズ エルエルシー 3d印刷用支持材料
WO2017196712A1 (en) * 2016-05-09 2017-11-16 Dispersol Technologies, Llc Improved drug formulations
WO2019043427A1 (en) 2017-09-01 2019-03-07 Jordan Sweden Medical And Sterilization Company FAST SELF-DISPERSION DOSAGE FORMS OF DEFERASIROX
CN109172532A (zh) * 2018-10-24 2019-01-11 北京哈三联科技有限责任公司 一种伊曲康唑分散片及其制备方法和应用
EP4021416A1 (en) * 2019-08-28 2022-07-06 Lubrizol Advanced Materials, Inc. Drug-polymer amorphous solid dispersions using linear poly (acrylic acid) polymers
KR102266145B1 (ko) * 2019-09-26 2021-06-17 대봉엘에스 주식회사 비정질 에피나코나졸 고체 분산체
WO2023025672A1 (en) 2021-08-25 2023-03-02 Basf Se Direct tableting auxiliary composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
EP0012523B2 (en) * 1978-11-20 1988-02-03 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
JPS5879915A (ja) * 1981-11-09 1983-05-13 Nippon Soda Co Ltd 棒状薬剤の製造方法
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
JPH0667840B2 (ja) * 1988-11-30 1994-08-31 萬有製薬株式会社 Nb―818の易吸収性製剤
US5028433A (en) 1988-11-30 1991-07-02 Banyu Pharmaceutical Co., Ltd. Readily absorbable drug formulation of NB-818
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
DK0580860T4 (da) * 1991-04-16 2005-03-21 Nippon Shinyaku Co Ltd Fremgangsmåde til fremstilling af en fast dispersion
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
CA2117651C (en) * 1992-03-18 2006-01-03 Jan Heeres Itraconazole and saperconazole stereoisomers
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
JP3413238B2 (ja) * 1993-03-31 2003-06-03 オリンパス光学工業株式会社 位相制御膜構造体
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
JP2948111B2 (ja) * 1994-09-16 1999-09-13 塩野義製薬株式会社 経口投与用油性組成物

Also Published As

Publication number Publication date
ID16926A (id) 1997-11-20
EE03902B1 (et) 2002-12-16
CZ293841B6 (cs) 2004-08-18
SI0904060T1 (en) 2004-04-30
DE69726729D1 (de) 2004-01-22
EA199800571A1 (ru) 1998-12-24
SK284145B6 (sk) 2004-10-05
EP0904060B1 (en) 2003-12-10
NO982599D0 (no) 1998-06-05
US6509038B2 (en) 2003-01-21
EP0904060A1 (en) 1999-03-31
AR007195A1 (es) 1999-10-13
IL124935A0 (en) 1999-01-26
US7081255B2 (en) 2006-07-25
NO320495B1 (no) 2005-12-12
AU722101B2 (en) 2000-07-20
NZ330739A (en) 1999-06-29
PL188566B1 (pl) 2005-02-28
PT904060E (pt) 2004-04-30
US20140134244A1 (en) 2014-05-15
TR199801225T2 (xx) 1998-11-23
BG64368B1 (bg) 2004-12-30
BR9706897A (pt) 1999-08-31
IL124935A (en) 2001-06-14
BG102532A (en) 1999-02-26
NO982599L (no) 1998-11-19
CZ188598A3 (cs) 1998-11-11
BR9706897B1 (pt) 2010-09-21
ATE255883T1 (de) 2003-12-15
ES2212810T3 (es) 2004-08-01
US20030082239A1 (en) 2003-05-01
JPH11509238A (ja) 1999-08-17
AU2956297A (en) 1997-12-09
CA2240161C (en) 2005-05-24
EA001219B1 (ru) 2000-12-25
CN1209740A (zh) 1999-03-03
US20010007678A1 (en) 2001-07-12
KR19990044257A (ko) 1999-06-25
US8591948B2 (en) 2013-11-26
WO1997044014A1 (en) 1997-11-27
HUP9901620A3 (en) 2000-03-28
CA2240161A1 (en) 1997-11-27
CN1165291C (zh) 2004-09-08
PL330931A1 (en) 1999-06-07
JP3391801B2 (ja) 2003-03-31
US9642806B2 (en) 2017-05-09
HK1018002A1 (en) 1999-12-10
DE69726729T2 (de) 2004-12-02
EE9800304A (et) 1999-02-15
US20060263436A1 (en) 2006-11-23
CY2434B1 (en) 2004-11-12
HU227745B1 (en) 2012-02-28
TW460282B (en) 2001-10-21
HRP970270B1 (en) 2005-02-28
HRP970270A2 (en) 1998-04-30
HUP9901620A2 (hu) 1999-10-28
MY123827A (en) 2006-06-30
MX9805418A (es) 1998-10-31
SK84898A3 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
DK0904060T3 (da) Antifungale præparater med forbedret biotilgængelighed
DK0921796T3 (da) Tetrahydrolipstatinholdige præparater
DE69720461D1 (de) Epoxybinder enthaltender flächenreissverschluss
ATE238707T1 (de) Bekleidungsstück
DE69512041T2 (de) Antifungale sordaridin-derivate
ATE281836T1 (de) Stabilisierte tibolone zubereitungen
DE59707298D1 (de) Desodorierende zubereitungen
DE59707873D1 (de) Farbstoffzubereitungen
NO985447L (no) Antifungalt preparat med forbedret biologisk tilgjengelighet
DE69508914D1 (de) Regenschirm
ATE246494T1 (de) Brausezubereitungen
DE59808302D1 (de) Farbstoffzubereitungen
DE69709463T2 (de) Reissverschluss
PT787861E (pt) Camisa
DE29715290U1 (de) Lichtschutzschirm
DE29603884U1 (de) Schultertragegestell
DE29610250U1 (de) Reißverschluß
FI2526U1 (fi) Teline
FI962404A0 (fi) Teline
DE29715071U1 (de) Sonnenschirm
DE29716763U1 (de) Sonnenschirm
UA1675S (uk) Зонт
SE9704446L (sv) Klädesplagg
KR960019766U (ko) 우산
KR960003758U (ko) 뒤집혀지지 않는 우산